Patents by Inventor Mohmed K. Anwer

Mohmed K. Anwer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7297784
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: November 20, 2007
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6656906
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 2, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Publication number: 20030186874
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Application
    Filed: January 24, 2003
    Publication date: October 2, 2003
    Applicant: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6562787
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: May 13, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6348568
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: February 19, 2002
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6258782
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: July 10, 2001
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Peptides useful in regulating the immune and nervous systems
    Patent number: 5215964
    Abstract: Pentapeptides are disclosed which are capable of regulating the function of cells of the mammalian immune and/or nervous system. Also provided are pharmaceutical compositions containing the peptides and methods of use thereof.
    Type: Grant
    Filed: June 3, 1991
    Date of Patent: June 1, 1993
    Assignee: Immunobiology Research Institute, Inc.
    Inventors: Gideon Goldstein, Tapan Audhya, George Heavner, Mohmed K. Anwer